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Aim: To evaluate the epidemiology, clinical features, and complications of brucellosis.
Materials and methods: Between January 2005 and December 2008, 161 patients with brucellosis who were admitted to our clinic were
evaluated prospectively.
Results: Of the patients, 97 (60.2%) were male, and the mean age was 47 ± 17 years (range: 16–79). There were 99 patients (61.5%) classified
as acute, 36 (22.4%) classified as subacute, and 6 (3.7%) classified as having a chronic infection. Relapse or reinfection was observed in 20
(12.4%) patients. Blood culture positivity rates were 60.7% and 44.8% among acute and subacute cases, respectively (P = 0.008). In 40 of
70 culture positive patients, standard Brucella tube agglutination titers were found above 1/1280 (P = 0.03). Blood culture positivity was
also higher in febrile patients (P = 0.001). Complications were detected in 66 of 161 patients (41.0%). Osteoarticular system involvement
was the most common complication (50 patients, 31.1%). Fever, positive blood cultures, and hepatosplenomegaly were significantly higher
in the group without complications (P < 0.05). Complications were significantly lower in acute infections than in subacute infections (P <
0.05). There were also higher complication rates detected in the patients with reinfection and relapse (P < 0.05).
Conclusion: In endemic regions, brucellosis is an important infectious disease causing chronic infections and complications.
Key words: Brucellosis, complication, relapse, reinfection

1. Introduction
Brucellosis is a serious public health problem in Turkey
(1,2). Inadequate control programs and uncontrolled animal
transportation increase the spread of brucellosis in some
regions (3–5). Human brucellosis is a multisystem disease
that may present a broad spectrum of clinical manifestations
(6,7). The wide spectrum of clinical involvement and the
nonspecific signs and symptoms interfere with the diagnosis
of many other infectious diseases (8–10). In this study, we
aimed to evaluate the epidemiology, clinical features, and
complications of brucellosis.
2. Materials and methods
2.1. Patients
This study was conducted between January 2005 and
December 2008 at the Infectious Diseases and Clinical
Microbiology Department of Ankara Numune Education
and Research Hospital. The study included 161 patients
with brucellosis who were followed-up with prospectively.
2.2. Diagnosis and collection of data
The diagnosis was established by positive standard Brucella
tube agglutination (STA) test (titer ≥ 1/160) and/or by
* Correspondence: drbican@gmail.com

isolation of Brucella species from blood or other body
fluids in patients with signs and symptoms compatible
with brucellosis.
Demographic, epidemiological, clinical, and laboratory
data were collected from all patients according to the
study protocol. Before starting therapy, 3 blood cultures
were drawn regardless of fever. Radiological methods were
used for the detection of complications. Cerebrospinal
fluid was examined in patients with signs compatible with
neurobrucellosis.
2.3. Classification and outcome
Based on the duration of the symptoms before admission
to the hospital, patients were classified as having acute (<2
months), subacute (2–12 months), or chronic (>12 months)
brucellosis. The disappearance of clinical symptoms and
the return of abnormal laboratory test results to normal
levels were accepted as recovery. In patients who completed
the treatment with improvement, recurrence of clinical
symptoms was accepted as relapse or reinfection.
2.4. Treatment
The patients without complications were treated with
standard combination therapy, which consisted of
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doxycycline (200 mg/day) plus rifampicin (600 mg/day)
for 6 weeks. In patients with osteoarticular involvement,
initially a 3-drug regiment (doxycycline at 200 mg/day,
rifampicin at 600 mg/day, and streptomycin at 1 g/day) was
applied for 3 weeks and then the therapy was completed
in 4–6 months with 2 drugs (doxycycline at 200 mg/day
plus rifampicin at 600 mg/day). Intravenous ceftriaxone (4
g/day for 2–3 weeks) was added to doxycycline (200 mg/
day) and rifampicin (600 mg/day) therapy for the patients
diagnosed with neurobrucellosis. Drug combinations were
modified according to the characteristics of the patients,
their response to the therapy, and the side effects of the
drugs.
2.5. Statistical analysis
Data were analyzed using SPSS 16.0. The Kolmogorov–
Smirnov test, Pearson chi-square test, Student t-test,
Fisher exact test and Mann–Whitney U test were used
for univariate analysis, and backwards logistic regression
analysis was used for multivariate analysis. P < 0.05 was
considered statistically significant.
3. Results
There were 161 patients included in the analyses. Of
these, 97 (60.2%) were male and the mean age was 47 ±
17 (range: 16–79) years old. Of the patients, 115 (71.4%)
were animal handlers and 128 (79.5%) were consumers of
unpasteurized dairy products. According to the duration

of symptoms, 99 patients (61.5%) were classified as acute,
36 (22.4%) were classified as subacute, and 6 (3.7%)
were classified as having chronic infection. Relapse or
reinfection was observed in 20 (12.4%) patients who had
been treated before. Reportedly, they had used the drugs
irregularly or continued to consume unpasteurized dairy
products.
On admission, the complaints were fever (77.7%),
sweating (57.8%), malaise (56.5%), lumbar pain (45.3%),
anorexia (41.6%), arthralgia (39.1%), myalgia (28%),
headache (26.1%), weight loss (25.5%), nausea and
vomiting (18%), neurological disorders (8.1%), and
testicular pain (5.2%). Physical examination revealed
high body temperature (>37.4 °C) (60.2%), limitations in
joint movements (41.6%), hepatomegaly (11.2%), signs of
arthritis (6.2%), neurological disorders (5.5%), orchitis
(7.2%), splenomegaly (4.4%), lymphadenopathy (1.9%),
and maculopapular rash (1.9%).
STA testing was positive for 157 patients (97.5%). In the
analysis of blood samples, 98 patients (60.8%) had anemia
(hemoglobin of <12.3 g/dL for females, <14.0 g/dL for
males), 30 (18.6%) had leukopenia (<4000/mm3), 6 (3.7%)
had leucocytosis (>11,300/mm3), and 24 (14.9%) had
thrombocytopenia (<150,000/mm3) (Table 1). Elevation
of c-reactive protein (CRP) (>5 mg/dL) and erythrocyte
sedimentation rate (ESR) (>20 mm/h) were detected in
134 (83.2%) and 100 patients (62.1%), respectively.

Table 1. Results of laboratory tests.
Laboratory tests

n

%

<14 for males, <12 for females

98

60.8

<4400

30

18.6

125

77.7

>11,300

6

3.7

<150,000

24

14.9

129

80.1

8

4.9

61

37.6

Sedimentation (>20 mm/h)

100

62.1

CRP (>5 mg/dL)

134

83.2

STA (>1/160)

157

97.6

Hemoglobin (g/dL)
White blood cell count (/mm3)
4400–11,300
Thrombocyte count (/mm3)
150,000–450,000
>450,000
Aspartate aminotransferase/alanine aminotransferase ratio (>50 IU)
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Of the 135 patients whose blood cultures were drawn,
Brucella spp. were grown in 70 cultures (51.9%). Blood
culture positivity rates were 60.7% and 44.8% in acute
and subacute patients, respectively. The difference was
statistically significant (P = 0.008). No positive blood
culture was detected in chronic patients. STA tests were
positive in all blood culture-positive patients. A significant
correlation was also detected between positive blood
cultures and STA titers, which were significantly higher
in culture-positive patients (P = 0.03). In 40 of 70 culture
positive patients (57%), STA titers were found above
1/1280. The rate of blood culture positivity was also higher
in febrile patients than afebrile patients (P = 0.001). From
70 blood culture-positive patients, 54 were febrile (77%).
Complications were detected in 66 of 161 patients
(41.0%) and were significantly lower in acute infections than
subacute infections (P < 0.05). The detected complication
rates were also higher in the patients with reinfection and
relapse (P < 0.05). Osteoarticular system involvement was
the most common complication (50 patients, 31.1%). Other
complications were neurobrucellosis (8 patients, 4.9%),
orchitis (7 patients, 4%), and hepatitis (1 patient, 0.6%)
(Table 2). Spondylitis was the most frequent osteoarticular
involvement and was detected in 37 patients (74.0%). In
the majority of cases, the lumbar spine was affected (17
cases, 44.7%). Paravertebral abscess was accompanied in
13 patients with spondylitis (35.1%). Other osteoarticular
involvements were sacroiliitis (10 patients, 20%) and
peripheral arthritis (8 patients, 16%). There were 4 patients

Table 2. Distribution of complications.
Patients
Complications

n

%

Osteoarticular involvement

50

31.1

Neurobrucellosis

8

4.9

Orchitis*

7

4.1

Hepatitis

1

0.6

Total

66

40.9

*Evaluated for male patients (n = 97).

with neurobrucellosis who had cranial nerve (C3, C7,
C8) involvement. CSF examination results were abnormal
(pleocytosis, high protein level, low glucose) and CSF
Brucella tube agglutination tests were positive (between
1:32 and 1:512) for all of them. In 2 patients, Brucella spp.
were grown in CSF cultures.
The patients with and without complications were
compared statistically and no significant differences were
detected between the 2 groups for age, sex, presence of
anemia, leukopenia and thrombocytopenia, or levels of
ESR, CRP, and STA (P > 0.05). However, fever, positive
blood cultures, and hepatosplenomegaly were significantly
higher in the group without complications (P < 0.05)
(Table 3).

Table 3. Comparison of noncomplicated and complicated cases.
Properties

Patients Noncomplicated

Complicated

n

%

n

%

Male

60

61.9

37

38.1

Female

35

Age, years (range)

47

P-value
0.365

54.7

29

45.3

(16–79)

51

(18–75)

0.211

Acute

68

68.7

31

31.3

0.002

Subacute

16

44.4

20

55.6

0.044

Relapse/reinfection

7

35.0

13

65

0.020

Fever

80

65.0

43

35.0

0.008

Hepatosplenomegaly

16

80.0

4

20.0

0.041

Anemia

58

59.2

40

40.8

0.954

Leukopenia

23

74.2

8

25.8

0.056

Thrombocytopenia

18

75.0

6

25.0

0.084

Blood culture positivity

50

71.4

20

28.6

<0.001

Sedimentation (range)

34

(2–103)

39

(3–300)

0.631

CRP (range)

32

(2–192)

28

(0.9–413)

0.558

STA (range)

1280

(40–10,240)

640

(0–10,240)

0.412
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Most of the patients (109, 67.7%) were treated with a
combination of doxycycline and rifampicin. There were
37 patients (23%) given a combination of rifampicin and
doxycycline plus streptomycin, and 8 patients (5.0%) were
treated with a combination of rifampicin and doxycycline
plus ceftriaxone (Table 4). Few patients came for follow-up
visits after discontinuation of the antibiotic therapy, and
no relapse or recurrence was detected.
4. Discussion
Osteoarticular infection is the most frequent complication
of brucellosis and its prevalence varies between 10% to
80% in several studies (2,11–15). In a study reported by
Bodur et al., brucellar spondylitis was diagnosed in 26 of
86 patients (30%) (16). In the present study, osteoarticular
involvement was detected in 31.1% of the patients as the
most frequent complication, and the spine was the most
affected site (74%). However, these data varied in different
studies. While Aygen et al. found that peripheral arthritis
was the most involved area (47.2%), in the study reported
by Kadanali et al., sacroiliitis was the body region most
infected by brucellosis (72.2%) (12,17). On the other
hand, in the study by Colmenero et al., it was suggested
that spondylitis was the most commonly affected
osteoarticular site with a rate of 47.4% (11). In our study,
similar to the study of Colmenero et al., spondylitis was
the most common osteoarticular infection of brucellosis.
In another study from Turkey, a total of 1028 brucellosis
patients were retrospectively analyzed. The most frequent
symptoms were arthralgia (73.7%) and fever (72.2%),
while the most common clinical findings were fever
(28.8%) and hepatomegaly (20.6%). Focal involvement
was found in 371 (36.1%) patients. The most frequent
involvement was osteoarticular involvement with 260
patients (25.3%). The overall relapse rate was 4.7% and
the highest rate (8.5%) was observed in patients with

osteoarticular infection. Antibiotic regimens including
doxycycline and streptomycin, with or without rifampin,
were more effective than others in osteoarticular infection
(18).
Spondylitis develops mainly in elderly males and in
those with a chronic disease. It occurs most frequently
in the lumbar region, followed by cervical and thoracic
locations (2,11,13,16). In the course of brucellar spondylitis,
paravertebral, epidural, and psoas abscess formation can
occur in varying prevalences (2,13,19,20). In the present
study, the lumbar spine was the most involved vertebral
region, and paravertebral abscesses were detected in 13
patients with spondylitis (35.1%).
Sacroiliitis is one of the most often reported
osteoarticular infections and is generally present with
spondylitis (2). Kadanali et al. and Taşova et al. reported
that sacroiliitis was the most common osteoarticular
involvement in brucellosis (17,21). While spondylitis is
seen in elderly males, sacroiliitis affects younger people
of both sexes. It is generally unilateral (2,13,22,23). In
our study, sacroiliitis was detected in 10 (20%) patients.
Of these cases, 6 were unilateral and there were 4 with
spondylitis. Peripheral arthritis is seen usually in younger
people during acute infection (1,22). It is commonly
presented as monoarthritis and rarely as oligoarthritis.
Knee and hip joints are the most commonly involved
joints (2,21,24,25). It is usually due to bacterial invasion
of the synovial structure and sometimes can be reactive
(26). Of our patients, 8 (16.0%) had peripheral arthritis,
and in 5 of these cases the knee was affected. All patients
experienced monoarticular involvement except for one.
In patients with spondylitis, duration of antibiotic
therapy must be longer than in those without spondylitis
(6,16). It was shown that the combination of doxycycline
plus streptomycin is more efficient than the combination
of doxycycline plus rifampicin. In the presence of

Table 4. Antimicrobial regiments and duration of the treatment.
Antimicrobial regiments

n

%

Duration

Rifampicin + doxycycline

109

67.7

6–8 weeks

*Doxycycline + streptomycin + rifampicin

37

23

4–6 months

**Rifampicin + doxycycline + ceftriaxone

8

5

2–10 months

Rifampicin + ciprofloxacin

2

1.2

4–6 months

Rifampicin + doxycycline + ciprofloxacin

2

1.2

3–6 months

Rifampicin + doxycycline + trimethoprim–sulfamethoxazole

2

1.2

3–6 months

Rifampicin + doxycycline + ofloxacin

1

0.7

6 months

*Streptomycin was given for the first 3 weeks. In 5 patients with spondylitis, antimicrobial therapy was extended to 9–10 months.
**Ceftriaxone was given for the first 4 weeks.
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paravertebral abscess, surgical treatment may also
be needed (12,27,28). In this study, patients with
osteoarticular complications received a combination of
doxycycline, rifampicin, and streptomycin for the first 3
weeks and thereafter the therapy was completed in 4–6
months with a doxycycline–rifampicin combination. In
5 patients with spondylitis, the antimicrobial therapy
was extended to 9–10 months because of delayed clinical
and radiological response. There were 2 patients with
paravertebral abscesses who underwent surgical drainage
in addition to antibiotic treatment. None of these patients
experienced recurrence.
Epididymo-orchitis is another manifestation of
brucellosis and is seen in 2%–20% of male patients. It is
seen generally in the course of acute disease and in younger
patients. The involvement is usually unilateral (2,7,29).
In our study, epididymo-orchitis was detected in 7 of 97
male patients and 6 of these had unilateral involvement. A
combination of doxycycline and rifampicin was given to
the patients for 6–8 weeks. In the follow-up examinations,
there was no recurrence.
Central nervous system involvement is an uncommon
complication of brucellosis reported in less than 5% of
patients in the literature, and it usually presents as acute
or chronic meningitides (2). While Bodur et al. detected
neurobrucellosis in 17.8% of patients, Yetkin et al.
reported this rate as 6.6% (30,31). The reason for the rate
differences may be associated with the different natures of
the patient populations referred to the hospitals and the
different times of the studies. The prevalence and nature of
the disease may vary with time. Neurobrucellosis has no
typical clinical picture or specific CSF findings. Imaging
findings of neurobrucellosis are divided into 4 categories,
namely normal, inflammation, white matter changes, and
vascular changes (32). Meningeal signs are also detected
in fewer than 50% of the patients. Thus, in brucellosis
patients with any neurological symptoms, CSF samples
must be obtained (30,31). Cranial nerve involvement is
rarely seen in brucellosis and optic, oculomotor, abducens,
facial, and vestibulocochlear nerves are most commonly
involved (30,31,33).
The optimal antimicrobial regimen and appropriate
duration of treatment of neurobrucellosis have not been
determined yet. They must be individualized. Combination
therapy with 2 or 3 antibiotics that penetrate the blood–
brain barrier is recommended for at least 2 months (2,6,30).
Bouza et al. recommended continuation of treatment
until patients recover and the CSF glucose level returns
to normal (33). The response to the treatment is usually
favorable in most patients. However, patients with severe
neurologic sequelae have been reported (2,30). In our
study, the patients with neurobrucellosis were treated with
a combination of doxycycline, rifampicin, and ceftriaxone

for the first 4 weeks and the therapy was completed in 2–10
months with doxycycline and rifampicin. Except for one
patient who died, all patients were cured without sequelae.
Antimicrobial susceptibility tests were not performed
for the isolated strains because of the high risk of
contagiousness among the laboratory staff and the tests’
low value for prediction of clinical efficacy. In general,
treatment failure is related to poor compliance of
patients and inappropriate antibiotic therapy rather than
antimicrobial resistance. Moreover, reports from Turkey
indicate that drug resistance is not a problem in this
country (34–36).
In general, the choice and duration of antimicrobial
regimen should be based on presence of focal disease or
underlying conditions. Most patients with acute brucellosis
respond well to the combination of doxycycline plus
aminoglycosides or rifampicin for 6 weeks. A combination
of doxycycline with trimethoprim–sulfamethoxazole,
or a quinolone plus rifampicin, are alternative treatment
choices. The duration of antimicrobial therapy may be
longer in patients with complications like spondylitis or
endocarditis (37). Research for simple, low-cost, and
effective treatment alternatives is in progress. In a recent
metaanalysis, it was suggested that the most effective
regimen was a combination of doxycycline for 45 days
with streptomycin for 14 days, or gentamycin for 7 days,
in noncomplicated brucellosis. The alternative was a
combination of doxycycline and rifampicin. Triple therapy
with doxycycline–rifampicin–aminoglycoside was not
recommended as the best regimen (38).
In brucellosis, the diagnosis is confirmed with the
isolation of Brucella spp. from blood, bone marrow, or
other tissues (2). Since culture techniques are lengthy,
risky processes that have low sensitivity, the diagnosis
of brucellosis is mostly based on high titers of specific
antibodies. The SAT is accepted as the reference method
in the serological diagnosis of human brucellosis. SAT
titers of ≥1:160 are consistent with active brucellosis
when accompanied by a compatible clinical course
and epidemiological history (39). In the present study,
a correlation was found between the presence of fever
and high STA titers, and a correlation was also detected
between blood culture positivity and acute disease.
These results are similar to the results of previous studies
reported by Gotuzzo et al. and Özkurt et al. (40,41). This
is probably due to the high risk of bacteremia during acute
infection. However, the bacteria can be found in blood
cultures of afebrile patients. Therefore, blood cultures
should be drawn also in patients without fever. Although
the isolation of the bacteria from blood cultures is very
important for the diagnosis of chronic infections, we
found no culture positivity in chronic cases. This may be
due to several factors, such as the low level of bacteremia
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and previous antibiotic usage. In a comparison of the cases
with and without complications, it was found that rates
of positive blood cultures, fever, and hepatosplenomegaly
were higher in noncomplicated cases. Considering that
positive blood cultures and fever are most common
in acute cases, this result indicates that complications
develop more frequently in subacute and chronic phases
of the disease than in the acute phase. It was shown that a
delay of more than 14 days in the diagnosis of brucellosis
significantly increased the risk of complications (P =
0.002). In addition, long-term follow-up exams indicated
that 64% of the patients developed recurrent symptoms
(42).

In conclusion, human brucellosis is a multisystem
disease and presents with a broad spectrum of clinical
manifestations. Although brucellosis is endemic in Turkey,
it often remains undiagnosed. Thus, healthcare workers
should always keep acute and chronic brucellosis in mind,
especially in differential diagnosis of infectious diseases
including osteoarticular, neurologic, hematologic, and
genitourinary disorders. Delayed diagnosis or inadequate
therapy may cause the development of chronic infections
and complications. A high cure rate can be achieved with
appropriate antibiotic combinations with an adequate
duration. Early and successful treatment is thus effective
to prevent the complications of brucellosis.
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